☆ 4.4 Article

Meropenem/Vaborbactam and Cefiderocol as Combination or Monotherapy to Treat Multi-Drug Resistant Gram-Negative Infections: A Regional Cross-Sectional Survey from Piedmont Infectious Disease Unit Network (PIDUN)

JOURNAL OF FUNCTIONAL BIOMATERIALS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

Mical Paul et al.

Summary: These guidelines address the targeted antibiotic treatment of 3GCephRE and carbapenem-resistant Gram-negative bacteria, focusing on the effectiveness of individual antibiotics and on combination versus monotherapy. Most recommendations are based on low-certainty evidence.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

添加到收藏夹

Article Microbiology

The Impact of Fast Microbiology in Intensive Care Units in the Era of Antibiotic Resistance: An Observational Retrospective Study

Mirko Muzzi et al.

Summary: This retrospective observational study compared the performance of FilmArray and the standard method in blood samples from ICU patients with suspected bloodstream infections. The results showed that FilmArray had high performance and could assist clinicians in decision-making processes, avoiding unnecessary drug use.

CURRENT MICROBIOLOGY (2022)

添加到收藏夹

Article Infectious Diseases

Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era

Gabriele Bianco et al.

Summary: The occurrence of multi-carbapenemase producers is not uncommon in Northern Italy area. MEV in combination with ATM might be considered as a potential therapeutic option, alternative to CZA plus ATM. CFDC susceptibility testing and synergy evaluation of ATM-based combinations should be performed in the lab routine to evaluate the most in vitro active antimicrobial regimen.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Microbiology

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

Marco Falcone et al.

Summary: Cefiderocol appears to be a promising therapeutic option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, with a potential protective effect on 30-day mortality. However, further studies are needed to address the issue of microbiological failure.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Infectious Diseases

Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective

Daniele Roberto Giacobbe et al.

Summary: In this perspective article, the available clinical data on novel agents for the treatment of CR-GNB VAP are discussed. Novel beta-lactams and beta-lactam/beta-lactamase inhibitor combinations are considered promising options for the treatment of CR-GNB VAP.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Safety and efficacy of cefiderocol for off-label treatment indications: A systematic review

Riyan Babidhan et al.

Summary: This systematic review examines the safety and efficacy of off-label use of cefiderocol for various infections, particularly for Pseudomonas aeruginosa and Acinetobacter baumannii infections. Combination antibiotic therapy was commonly used, and cefiderocol-related side effects were rare.

PHARMACOTHERAPY (2022)

添加到收藏夹

Article Microbiology

New evidence in severe pneumonia: meropenem-vaborbactam

María Forteza Guillot et al.

Revista Espanola de Quimioterapia (2022)

添加到收藏夹

Article Infectious Diseases

An Observational Study of MDR Hospital-Acquired Infections and Antibiotic Use during COVID-19 Pandemic: A Call for Antimicrobial Stewardship Programs

Nour Shbaklo et al.

Summary: The COVID-19 pandemic has led to major adjustments in healthcare systems and has caused an increase in multidrug-resistant (MDR) hospital-acquired infections (HAIs) at Molinette Hospital. The study also found changes in antibiotic consumption, with a reduction in fluoroquinolone use and an increase in the use of fourth- and fifth-generation cephalosporins and piperacillin-tazobactam during the COVID-19 period. The findings highlight the need for improved infection control practices and microbiological diagnosis during pandemics.

ANTIBIOTICS-BASEL (2022)

添加到收藏夹

Review Infectious Diseases

Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review

Julie Gorham et al.

Summary: This article summarizes pharmacokinetic studies on novel antibiotics in critically ill patients, aiming to guide clinicians in choosing the best dosage regimens.

ANTIBIOTICS-BASEL (2022)

添加到收藏夹

Review Chemistry, Medicinal

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians

Luigi Principe et al.

Summary: Bacterial resistance mechanisms are continuously and rapidly evolving, especially for Gram-negative bacteria. The strategy of developing new beta-lactam/beta-lactamase inhibitors (BLs/BLIs) combinations has been successful, and data on several compounds are becoming available. Cefiderocol, with its unique mechanism of action, warrants separate discussion.

PHARMACEUTICALS (2022)

添加到收藏夹

Article Infectious Diseases

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti et al.

Summary: The study assessed the efficacy and safety of cefiderocol versus best available therapy in the treatment of patients with carbapenem-resistant Gram-negative infections. Cefiderocol showed similar clinical and microbiological efficacy to best available therapy in this heterogeneous patient population with infections caused by carbapenem-resistant Gram-negative bacteria, suggesting it as an option for the treatment of carbapenem-resistant infections in patients with limited treatment options.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Richard G. Wunderink et al.

Summary: Cefiderocol was found to be non-inferior to high-dose, extended-infusion meropenem in terms of all-cause mortality on day 14 in patients with Gram-negative nosocomial pneumonia, with similar tolerability. This suggests that cefiderocol is a potential option for the treatment of patients with nosocomial pneumonia, including those caused by multidrug-resistant Gram-negative bacteria.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Infectious Diseases

Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among Enterobacterales and Other Gram-Negative Bacteria

Glen T. Hansen

Summary: Carbapenems are antibiotics used to treat Gram-negative bacteria infections, but carbapenem-resistant Enterobacterales (CRE) have emerged globally, posing a significant public health issue. Different types of carbapenemase enzymes are spreading rapidly, requiring active surveillance and therapeutic strategies.

INFECTIOUS DISEASES AND THERAPY (2021)

添加到收藏夹

Article Medicine, General & Internal

Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective

Silvia Corcione et al.

Summary: In the past decade, novel cephalosporins have shown promising microbiological susceptibility in septic and bacteremic patients, providing potential solutions for severe infections. Further pharmacological data is required to determine optimal dosing and prevent sub-therapeutic drug levels. New cephalosporins have opened up new prospects for the treatment of infectious diseases.

FRONTIERS IN MEDICINE (2021)

添加到收藏夹

Review Pharmacology & Pharmacy

Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections

Yahiya Y. Syed

Summary: Cefiderocol is a cephalosporin with activity against carbapenem-resistant bacteria and nonfermenters, using the bacteria's iron uptake system to disrupt the cell wall and kill the bacteria. It has shown good effectiveness and safety in clinical trials for various serious bacterial infections, providing a useful addition to treatment options for adults with limited choices.

DRUGS (2021)

添加到收藏夹

Article Infectious Diseases

Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study

Mario Tumbarello et al.

Summary: The study found that meropenem/vaborbactam therapy is effective for treating serious KPC-producing Klebsiella pneumoniae infections, even when there is resistance to ceftazidime/avibactam. Clinical cure rates were high, but there were cases of recurrence and mortality in patients treated with this combination therapy.

JAC-ANTIMICROBIAL RESISTANCE (2021)

添加到收藏夹

Article Infectious Diseases

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study

Renato Pascale et al.

Summary: This study confirms the potential role of cefiderocol in the treatment of CR-Ab infection, but larger clinical studies are needed for further validation.

JAC-ANTIMICROBIAL RESISTANCE (2021)

添加到收藏夹

Article Infectious Diseases

Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study

Renato Pascale et al.

Summary: This study analyzed the impact of cefiderocol use on patients with severe COVID-19 admitted to the ICU and further diagnosed with carbapenem-resistant Acinetobacter baumannii (CR-Ab) infection. The results suggest that cefiderocol may have a potential role in the treatment of CR-Ab infection, but larger clinical studies are needed for confirmation.

JAC-ANTIMICROBIAL RESISTANCE (2021)

添加到收藏夹

Article Microbiology

Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections

Renee Ackley et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

添加到收藏夹

Article Infectious Diseases

Perceived differences between intensivists and infectious diseases consultants facing antimicrobial resistance: a global cross-sectional survey

Jordi Rello et al.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship

Shio-Shin Jean et al.

DRUGS (2019)

添加到收藏夹

Article Medicine, General & Internal

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial

Keith S. Kaye et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

添加到收藏夹

Article Infectious Diseases

Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Richard G. Wunderink et al.

INFECTIOUS DISEASES AND THERAPY (2018)

添加到收藏夹

Article Critical Care Medicine

Influence of an Infectious Diseases Specialist on ICU Multidisciplinary Rounds

David N. Gilbert

CRITICAL CARE RESEARCH AND PRACTICE (2014)

添加到收藏夹

Article Pharmacology & Pharmacy

Multidrug-Resistant Gram-Negative Bacterial Infections: Are you Ready for the Challenge?

Daniel Curcio

CURRENT CLINICAL PHARMACOLOGY (2014)

添加到收藏夹

Article Public, Environmental & Occupational Health

Role of the infectious diseases specialist consultant on the appropriateness of antimicrobial therapy prescription in an intensive care unit

Enrico Raineri et al.

AMERICAN JOURNAL OF INFECTION CONTROL (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.